Headlines about PRA Health Sciences (NASDAQ:PRAH) have trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.9958699788036 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- 4 Attractive Stocks to Buy in an Evolving Healthcare Space – Nasdaq (nasdaq.com)
- PRA Health Sciences, Inc. – Value Analysis (NASDAQ:PRAH) : December 6, 2017 (finance.yahoo.com)
- Why Intrexon (XON) Could Be Positioned for a Slump (finance.yahoo.com)
- Financial Comparison: Celator Pharmaceuticals (CPXX) vs. PRA Health Sciences (PRAH) (americanbankingnews.com)
PRA Health Sciences (NASDAQ:PRAH) traded up $0.46 on Wednesday, hitting $81.46. 301,706 shares of the company were exchanged, compared to its average volume of 527,577. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. The company has a market capitalization of $5,150.00, a P/E ratio of 29.60, a price-to-earnings-growth ratio of 1.39 and a beta of 0.40. PRA Health Sciences has a twelve month low of $52.76 and a twelve month high of $84.38.
PRAH has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Credit Suisse Group boosted their target price on shares of PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. SunTrust Banks reaffirmed a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Citigroup reaffirmed a “buy” rating and issued a $93.00 target price (up from $90.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $92.00 target price (up from $88.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $89.09.
In related news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3078495/pra-health-sciences-prah-receives-daily-news-sentiment-rating-of-0-17.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.